TargetMol

Zotepine

Product Code:
 
TAR-T19680
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T19680-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-2mg2mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-5mg5mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-1mL1 mL * 10 mM (in DMSO)£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-10mg10mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-25mg25mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-50mg50mg£503.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-100mg100mg£687.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic, and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively. Zotepine is a second-generation antipsychotic with a primary use as a treatment for schizophrenia, although clinical trials have been conducted into its efficacy as an antimanic agent in patients with acute bipolar mania.
CAS:
26615-21-4
Formula:
C18H18ClNOS
Molecular Weight:
331.86
Pathway:
GPCR/G Protein; Neuroscience; Immunology/Inflammation
Purity:
0.98
SMILES:
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor; Histamine Receptor

Documents

References

1. Chan HY, Lin AS, Chen KP, Cheng JS, Chen YY, Tsai CJ. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. J Clin Psychopharmacol. 2013 Dec;33(6):747-52. doi: 10.1097/JCP.0b013e31829e8168. PubMed PMID: 24100785. 2. Lin CC, Chiu HJ, Chen JY, Liou YJ, Wang YC, Chen TT, Bai YM. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol. 2013 Apr;33(2):211-4. doi: 10.1097/JCP.0b013e31828700c7. PubMed PMID: 23422395. 3. Khairkar P, Gupta N, Varma SK. Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia. Indian J Pharmacol. 2013 Jan-Feb;45(1):95-7. doi: 10.4103/0253-7613.106447. PubMed PMID: 23543675; PubMed Central PMCID: PMC3608308. 4. Chen IM, Hsieh MH, Hwang TJ, Liu CC. Zotepine-related myopathy in a patient with schizophrenia. Eur J Clin Pharmacol. 2013 Mar;69(3):725-6. doi: 10.1007/s00228-012-1346-y. Epub 2012 Jul 14. PubMed PMID: 22797903.